Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for TXT, MGNX and MTCH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Wednesday, 09 October 2019 05:20 PM

Levi & Korsinsky, LLP

Topic:
5

NEW YORK, NY / ACCESSWIRE / October 9, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Textron Inc. (NYSE:TXT)

Lawsuit on behalf of: investors who purchased January 31, 2018 - October 17, 2018
Lead Plaintiff Deadline: October 21, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/textron-inc-loss-form?prid=3886&wire=1

According to the filed complaint, during the class period, Textron Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) end market sales of Arctic Cat products were slowing, resulting in a massive glut of old Arctic Cat inventory on dealers' floors; (2) in order to clear out this old inventory, the Company provided significant price discounts, which negatively impacted Textron's earnings; and (3) as a result, Textron's positive statements about Arctic Cat's business, operations, and prospects lacked a reasonable basis.

MacroGenics, Inc. (NASDAQGS:MGNX)

Lawsuit on behalf of: investors who purchased February 6, 2019 - June 3, 2019
Lead Plaintiff Deadline: November 12, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/macrogenics-inc-loss-form?prid=3886&wire=1

According to the filed complaint, during the class period, MacroGenics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had conducted the progression-free survival ("PFS") and first interim overall survival ("OS") analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.

Match Group, Inc. (NASDAQ:MTCH)

Lawsuit on behalf of: investors who purchased August 6, 2019 - September 25, 2019
Lead Plaintiff Deadline: December 2, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/match-group-inc-loss-form?prid=3886&wire=1

According to the filed complaint, during the class period, Match Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company used fake love interest ads to convince customers to buy and upgrade subscriptions; (2) the Company made it difficult and confusing for consumers to cancel their subscriptions; (3) as a result, the Company was reasonably likely to be subject to regulatory scrutiny; (4) the Company lacked adequate disclosure controls and procedures; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
5
Back to newsroom
Back to Newsroom
Share by: